3.146.176.112
dgid:
enl:
npi:0
-Advertisement-
Oculoplastics

Thyroid eye disease takes center stage at Oculofacial Plastic Surgery Subspecialty Day 2020

Posted on

Several sessions during the Oculofacial Plastic Surgery Subspecialty Day 2020 will focus on thyroid eye disease (TED) and recent advances in this area.

During the virtual live broadcast of the session “TED Talks,” attendees will hear from experts in the field on everything from where to start when treating a patient with newly diagnosed TED to what all ophthalmologists should know about teprotumumab (Horizon Therapeutics).

Teprotumumab was approved by the U.S. Food and Drug Administration in January 2020 and is the first drug approved for the treatment of adults with TED.

The TED Talks (session: OCU03V) start Friday, 12:35PM.

Other sessions during AAO 2020 Virtual highlighting TED include:

Ask the Experts Live: New Frontiers in Thyroid Eye Disease Management
Saturday, 2:35PM – 3:05PM PST
Session: ASK04V (Virtual Meeting Live Broadcast)

Managing TED: A Case-Based Course
Sunday, 1:00PM – 1:45PM PST
Session: 449V (Virtual Meeting Live Broadcast)

Surgical and Nonsurgical Intervention in Thyroid Eye Disease: A Video-Based Symposium
Session: 707 (On-Demand)  

-Advertisement-
Related Articles
Gail Devers Partners with the Graves’ Community to Focus on Thyroid Eye Disease
Jul 15, 2021
Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
Jul 12, 2021
Mycophenolate mofetil appears to be effective second-line treatment for TED
Jun 01, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-